Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer
NCT05808582 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2023-04-14
Summary
evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC
Conditions
- Hormone Receptor-positive Advanced Breast Cancer
Interventions
- DRUG
-
chidamide，fulvestrant
chidamide combined with fulvestrant
Sponsors & Collaborators
-
The First Affiliated Hospital with Nanjing Medical University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-01
- Primary Completion
- 2023-09-01
- Completion
- 2024-09-01
More Related Trials
-
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
NCT05890287 ·Status: RECRUITING ·Phase: NA
-
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
NCT05983107 ·Status: RECRUITING ·Phase: PHASE2
-
500mg Fulvestrant in HR+ MBC
NCT03708432 ·Status: COMPLETED
-
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
NCT05586841 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
NCT05186545 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
NCT05400993 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer
NCT05044988 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
NCT06172322 ·Status: RECRUITING ·Phase: PHASE1
-
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
NCT05075512 ·Status: RECRUITING ·Phase: PHASE2
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
Fulvestrant 500mg in Patients With Advanced Breast Cancer
NCT02909361 ·Status: UNKNOWN
-
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
NCT05759572 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
NCT04582955 ·Status: UNKNOWN ·Phase: NA
-
500mg Fulvestrant Versus Exemestane in MBC
NCT03575260 ·Status: COMPLETED
-
A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
NCT05504213 ·Status: RECRUITING ·Phase: PHASE1
-
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
NCT06561022 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
NCT07333937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib
NCT05464173 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04355858 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
NCT07005557 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
NCT03695341 ·Status: COMPLETED
-
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
NCT05889871 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
NCT06447623 ·Status: RECRUITING ·Phase: PHASE3
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2